Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity.
Talaromyces marneffei
IEI
IL-12/IFN-γ axis
STAT1-GOF
STAT3-LOF
XHIM
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
received:
09
01
2024
accepted:
30
08
2024
medline:
26
9
2024
pubmed:
26
9
2024
entrez:
26
9
2024
Statut:
epublish
Résumé
Talaromyces marneffei (T. marneffei) is an opportunistic pathogen that causes endemic mycoses, which could lead to multiple organ damage. Talaromycosis is frequently disregarded as an early cautionary sign of immune system disorders in non-HIV-infected children. We conduct a comprehensive review of the genotypes and clinical features of talaromycosis in patients with IEI to enhance clinical awareness regarding T. marneffei as a potential opportunistic pathogen in individuals with immune deficiencies. A systematic literature review was performed by searching PubMed, Cochrane Central Register of Controlled Trials, Web of Science, EMBASE, and Scopus. Data on IEI patients with talaromycosis, including genotypes and their immunological and clinical features, were collected. Fifty patients with talaromycosis and IEI were included: XHIM (30.0%), STAT3-LOF deficiency (20.0%), STAT1-GOF (20.0%), IL2RG (6.00%), IFNGR1 (6.0%), IL12RB1 (4.0%), CARD9 (4.0%), COPA (4.0%), ADA (2.0%), RELB deficiency (2.0%), and NFKB2 (2.0%). Common symptoms of respiratory (43/50, 86.0%), skin (17/50, 34.0%), lymph node (31/50, 62.0%), digestive (34/50, 68.0%), and hematologic (22/50, 44.0%) systems were involved. The CT findings of the lungs may include lymph node calcification (9/30), interstitial lesions (8/30), pulmonary cavities (8/30), or specific pathogens (4/30), which could be easily misdiagnosed as tuberculosis infection. Amphotericin B (26/43), Voriconazole (24/43) and Itraconazole (22/43) were used for induction therapy. Ten patients were treated with Itraconazole sequentially and prophylaxis. 68.0% (34/50) of patients were still alive, and 4.0% (2/50) of were lost to follow-up. The disseminated T. marneffei infection resulted in the deaths of 14 individuals. The XHIM, STAT1-GOF, and STAT3-LOF demonstrated the highest susceptibility to talaromycosis, indicating the potential involvement of cellular immunity, IL-17 signaling, and the IL-12/IFN-γ axis in T. marneffei defense. T. marneffei infection may serve as an early warning indicator of IEI. For IEI patients suspected of T. marneffei, metagenomic next-generation sequencing (mNGS) could rapidly and effectively identify the causative pathogen. Prompt initiation of antifungal therapy is crucial for optimizing patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Talaromyces marneffei (T. marneffei) is an opportunistic pathogen that causes endemic mycoses, which could lead to multiple organ damage. Talaromycosis is frequently disregarded as an early cautionary sign of immune system disorders in non-HIV-infected children.
OBJECTIVE
OBJECTIVE
We conduct a comprehensive review of the genotypes and clinical features of talaromycosis in patients with IEI to enhance clinical awareness regarding T. marneffei as a potential opportunistic pathogen in individuals with immune deficiencies.
METHODS
METHODS
A systematic literature review was performed by searching PubMed, Cochrane Central Register of Controlled Trials, Web of Science, EMBASE, and Scopus. Data on IEI patients with talaromycosis, including genotypes and their immunological and clinical features, were collected.
RESULTS
RESULTS
Fifty patients with talaromycosis and IEI were included: XHIM (30.0%), STAT3-LOF deficiency (20.0%), STAT1-GOF (20.0%), IL2RG (6.00%), IFNGR1 (6.0%), IL12RB1 (4.0%), CARD9 (4.0%), COPA (4.0%), ADA (2.0%), RELB deficiency (2.0%), and NFKB2 (2.0%). Common symptoms of respiratory (43/50, 86.0%), skin (17/50, 34.0%), lymph node (31/50, 62.0%), digestive (34/50, 68.0%), and hematologic (22/50, 44.0%) systems were involved. The CT findings of the lungs may include lymph node calcification (9/30), interstitial lesions (8/30), pulmonary cavities (8/30), or specific pathogens (4/30), which could be easily misdiagnosed as tuberculosis infection. Amphotericin B (26/43), Voriconazole (24/43) and Itraconazole (22/43) were used for induction therapy. Ten patients were treated with Itraconazole sequentially and prophylaxis. 68.0% (34/50) of patients were still alive, and 4.0% (2/50) of were lost to follow-up. The disseminated T. marneffei infection resulted in the deaths of 14 individuals.
CONCLUSIONS
CONCLUSIONS
The XHIM, STAT1-GOF, and STAT3-LOF demonstrated the highest susceptibility to talaromycosis, indicating the potential involvement of cellular immunity, IL-17 signaling, and the IL-12/IFN-γ axis in T. marneffei defense. T. marneffei infection may serve as an early warning indicator of IEI. For IEI patients suspected of T. marneffei, metagenomic next-generation sequencing (mNGS) could rapidly and effectively identify the causative pathogen. Prompt initiation of antifungal therapy is crucial for optimizing patient outcomes.
Identifiants
pubmed: 39325235
doi: 10.1007/s10875-024-01798-3
pii: 10.1007/s10875-024-01798-3
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Subventions
Organisme : National Natural Science Foundation of China
ID : 82070135
Organisme : National Key R&D Program of China
ID : 2021YFC2700804
Organisme : CQMU Program for Youth Innovation in Future Medicine
ID : W0100
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Cao C, Xi L, Chaturvedi V. Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: insights into the clinical trends of a major fungal disease 60 years after the discovery of the pathogen. Mycopathologia. 2019;184(6):709–20.
doi: 10.1007/s11046-019-00410-2
pubmed: 31811603
Capponi M, Segretain G, Sureau P. Penicillosis from Rhizomys sinensis. Bull Soc Pathol Exot Filiales. 1956;49(3):418–21.
pubmed: 13364636
Qiu Y, Feng X, Zeng W, Zhang H, Zhang J. Immunodeficiency disease spectrum in HIV-negative individuals with talaromycosis. J Clin Immunol. 2021;41(1):221–3.
doi: 10.1007/s10875-020-00869-5
pubmed: 32996007
Liu L, Sun B, Ying W, Liu D, Wang Y, Sun J, et al. Rapid diagnosis of Talaromyces marneffei infection by metagenomic next-generation sequencing technology in a Chinese cohort of inborn errors of immunity. Front Cell Infect Microbiol. 2022;12:987692.
doi: 10.3389/fcimb.2022.987692
pubmed: 36159645
pmcid: 9493038
Qiu Y, Zeng W, Zhang H, Zhong X, Tang S, Zhang J. Comparison of pleural effusion features and biomarkers between talaromycosis and tuberculosis in non-human immunodeficiency virus-infected patients. BMC Infect Dis. 2019;19(1):745.
doi: 10.1186/s12879-019-4376-6
pubmed: 31455239
pmcid: 6712812
Fan JH, Luo HY, Yang LG, Wang MY, Xiao ZH. Penicilliosis marneffei in HIV negative children: three case reports. Ann Palliat Med. 2021;10(7):8437–47.
doi: 10.21037/apm-20-2056
pubmed: 33894704
Yang D, Shen LX, Chen RF, Fu Y, Xu HY, Zhang LN, et al. The Effect of Talaromyces marneffei Infection on CD86 Expression in THP-1 Cells. Infect Drug Resist. 2021;14:651–60.
doi: 10.2147/IDR.S297160
pubmed: 33642869
pmcid: 7903953
You CY, Hu F, Lu SW, Pi DD, Xu F, Liu CJ, et al. Talaromyces marneffei infection in an HIV-negative child with a CARD9 mutation in china: a case report and review of the literature. Mycopathologia. 2021;186(4):553–61.
doi: 10.1007/s11046-021-00576-8
pubmed: 34224076
pmcid: 8256645
Ba H, Peng H, Cheng L, Lin Y, Li X, He X, et al. Case report: talaromyces marneffei Infection in a Chinese child with a complex heterozygous CARD9 mutation. Front Immunol. 2021;12:685546.
doi: 10.3389/fimmu.2021.685546
pubmed: 34234782
pmcid: 8255793
Guo J, Li BK, Li TM, Wei FL, Fu YJ, Zheng YQ, et al. Characteristics and prognosis of talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China. Mycopathologia. 2019;184(6):735–45.
doi: 10.1007/s11046-019-00373-4
pubmed: 31473910
Du X, Tang W, Chen X, Zeng T, Wang Y, Chen Z, et al. Clinical, genetic and immunological characteristics of 40 Chinese patients with CD40 ligand deficiency. Scand J Immunol. 2019;90(4):e12798.
doi: 10.1111/sji.12798
pubmed: 31179555
Chen X, Xu Q, Li X, Wang L, Yang L, Chen Z, et al. Molecular and phenotypic characterization of nine patients with STAT1 GOF mutations in China. J Clin Immunol. 2020;40(1):82–95.
doi: 10.1007/s10875-019-00688-3
pubmed: 31686315
Zhang W, Ye J, Qiu C, Wang L, Jin W, Jiang C, et al. Rapid and precise diagnosis of T. marneffei pulmonary infection in a HIV-negative patient with autosomal-dominant STAT3 mutation: a case report. Ther Adv Respir Dis. 2020;14:1753466620929225.
doi: 10.1177/1753466620929225
pubmed: 32482141
pmcid: 7268139
Xue X, Zou J, Fang W, Liu X, Chen M, Arastehfar A, et al. Characteristics and prognosis of talaromyces marneffei infection in HIV-positive children in Southern China. Mycopathologia. 2022;187(2–3):169–80.
doi: 10.1007/s11046-021-00614-5
pubmed: 35157189
Li X, Hu W, Wan Q, Lei Q, Sun C, Hou Z, et al. Non-HIV talaromycosis: radiological and clinical analysis. Medicine (Baltimore). 2020;99(10):e19185.
doi: 10.1097/MD.0000000000019185
pubmed: 32150056
Ding X, Huang H, Zhong L, Chen M, Peng F, Zhang B, et al. Disseminated talaromyces marneffei infection in a non-HIV infant with a homozygous private variant of RELB. Front Cell Infect Microbiol. 2021;11:605589.
doi: 10.3389/fcimb.2021.605589
pubmed: 33791233
pmcid: 8005656
Zhan Y, Lu C, Li S, Zhao J, Li Z, Gu Y, et al. Successful management of mixed mycosis in HIV-negative patients with different immune status: a case series report. Front Cell Infect Microbiol. 2022;12:851891.
doi: 10.3389/fcimb.2022.851891
pubmed: 35310841
pmcid: 8930925
Pan M, Huang J, Qiu Y, Zeng W, Li Z, Tang S, et al. Assessment of talaromyces marneffei infection of the intestine in three patients and a systematic review of case reports. Open Forum Infect Dis. 2020;7(6):ofaa128.
doi: 10.1093/ofid/ofaa128
pubmed: 32523970
pmcid: 7264840
Qiu Y, Zhang J, Liu G, Zhong X, Deng J, He Z, et al. Retrospective analysis of 14 cases of disseminated Penicillium marneffei infection with osteolytic lesions. BMC Infect Dis. 2015;15:47.
doi: 10.1186/s12879-015-0782-6
pubmed: 25656710
pmcid: 4322545
Li D, Liang H, Zhu Y, Chang Q, Pan P, Zhang Y. Clinical Characteristics, laboratory findings, and prognosis in patients with talaromyces marneffei infection across various immune statuses. Front Med (Lausanne). 2022;9:841674.
doi: 10.3389/fmed.2022.841674
pubmed: 35492344
Shi M, Lin J, Wei W, Qin Y, Meng S, Chen X, et al. Machine learning-based in-hospital mortality prediction of HIV/AIDS patients with Talaromyces marneffei infection in Guangxi, China. PLoS Negl Trop Dis. 2022;16(5):e0010388.
doi: 10.1371/journal.pntd.0010388
pubmed: 35507586
pmcid: 9067679
Hu Y, Zhang J, Li X, Yang Y, Zhang Y, Ma J, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia. 2013;175(1–2):57–67.
doi: 10.1007/s11046-012-9577-0
pubmed: 22983901
Thu NTM, Chan JFW, Ly VT, Ngo HT, Hien HTA, Lan NPH, et al. Superiority of a novel Mp1p antigen detection enzyme immunoassay compared to standard BACTEC blood culture in the diagnosis of talaromycosis. Clin Infect Dis. 2021;73(2):e330–6.
doi: 10.1093/cid/ciaa826
pubmed: 32564074
Pruksaphon K, Intaramat A, Simsiriwong P, Mongkolsuk S, Ratanabanangkoon K, Nosanchuk JD, et al. An inexpensive point-of-care immunochromatographic test for Talaromyces marneffei infection based on the yeast phase specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin. PLoS Negl Trop Dis. 2021;15(5):e0009058.
doi: 10.1371/journal.pntd.0009058
pubmed: 33945531
pmcid: 8096094
Zeng Q, Jin Y, Yin G, Yang D, Li W, Shi T, et al. Peripheral immune profile of children with Talaromyces marneffei infections: a retrospective analysis of 21 cases. BMC Infect Dis. 2021;21(1):287.
doi: 10.1186/s12879-021-05978-z
pubmed: 33743629
pmcid: 7980795
Liu D, Zhong LL, Li Y, Chen M. Recurrent fever, hepatosplenomegaly and eosinophilia in a boy. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18(11):1145–9.
pubmed: 27817782
Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med. 2017;376(24):2329–40.
doi: 10.1056/NEJMoa1613306
pubmed: 28614691
Nelson M, Dockrell D, Edwards S, Subcommittee BG, Angus B, Barton S, et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12(Suppl 2):1–140.
doi: 10.1111/j.1468-1293.2011.00944_1.x
pubmed: 21851517
Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutierrez F, et al. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enferm Infecc Microbiol Clin. 2016;34(8):516.e1-e18.
doi: 10.1016/j.eimc.2016.02.004
pubmed: 26976381
Pan M, Qiu Y, Zeng W, Tang S, Wei X, Zhang J. Disseminated Talaromyces marneffei infection presenting as multiple intestinal perforations and diffuse hepatic granulomatous inflammation in an infant with STAT3 mutation: a case report. BMC Infect Dis. 2020;20(1):394.
doi: 10.1186/s12879-020-05113-4
pubmed: 32493232
pmcid: 7271463
Klus J, Ly VT, Chan C, Le T. Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort. Med Mycol. 2021;59(4):392–9.
doi: 10.1093/mmy/myab005
pubmed: 33644813
pmcid: 8023982
Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis. 2013;13:464.
doi: 10.1186/1471-2334-13-464
pubmed: 24094273
pmcid: 3851520
Tang WJ, An YF, Dai RX, Wang QH, Jiang LP, Tang XM, et al. Clinical, molecular, and T cell subset analyses in a small cohort of Chinese patients with hyper-IgM syndrome type 1. Hum Immunol. 2014;75(7):633–40.
doi: 10.1016/j.humimm.2014.04.014
pubmed: 24768948
Li Y, Yang J. Analysis of Talaromycosis in children with primary immunodeficiencies based on clinical phenotype and genotype(13). Shantou University.2021;R725.9. https://d.wanfangdata.com.cn/thesis/ChJUaGVzaXNOZXdTMjAyMjA5MDESCUQwMjQzNDYwMBoIdTd4Mm50ZzE%3D . Accessed 11 Nov 2021.
Lee PP, Lao-Araya M, Yang J, Chan KW, Ma H, Pei LC, et al. Application of flow cytometry in the diagnostics pipeline of primary immunodeficiencies underlying disseminated talaromyces marneffei infection in HIV-negative children. Front Immunol. 2019;10:2189.
doi: 10.3389/fimmu.2019.02189
pubmed: 31572394
pmcid: 6753679
Lee PP, Mao H, Yang W, Chan KW, Ho MH, Lee TL, et al. Penicillium marneffei infection and impaired IFN-gamma immunity in humans with autosomal-dominant gain-of-phosphorylation STAT1 mutations. J Allergy Clin Immunol. 2014;133(3):894-6.e5.
doi: 10.1016/j.jaci.2013.08.051
pubmed: 24188975
Fan H, Huang L, Yang D, Lin Y, Lu G, Xie Y, et al. Pediatric hyperimmunoglobulin E syndrome: a case series of 4 children in China. Medicine (Baltimore). 2018;97(14):e0215.
doi: 10.1097/MD.0000000000010215
pubmed: 29620631
Chen K, Tan J, Qian S, Wu S, Chen Q. Case report: disseminated talaromyces marneffei infection in a patient with chronic mucocutaneous candidiasis and a novel STAT1 gain-of-function mutation. Front Immunol. 2021;12:682350.
doi: 10.3389/fimmu.2021.682350
pubmed: 34421897
pmcid: 8374937
Wang C, Wang N, Feng J, Li Y, Fang W, Zhang X, et al. Two cases of congenital immunodeficiency with disseminated infection of cyanobacteria marneffei and literature review. Chin Pediatr Emerg Med. 2020;27(11):861–4. https://doi.org/10.3760/cma.j.issn.1673-4912.2020.11.015 .
doi: 10.3760/cma.j.issn.1673-4912.2020.11.015
Lee PP, Chan KW, Lee TL, Ho MH, Chen XY, Li CH, et al. Penicilliosis in children without HIV infection–are they immunodeficient? Clin Infect Dis. 2012;54(2):e8–19.
doi: 10.1093/cid/cir754
pubmed: 22065867
Guo J, Ning XQ, Ding JY, Zheng YQ, Shi NN, Wu FY, et al. Anti-IFN-gamma autoantibodies underlie disseminated Talaromyces marneffei infections. J Exp Med. 2020;217(12). https://doi.org/10.1084/jem.20190502
Lin L, Fan H, Zhang D, Lu G. Talaromyces marneffei infection associated with bronchiolitis obliterans in an HIV-negative child: a case report. BMC Infect Dis. 2022;22(1):468.
doi: 10.1186/s12879-022-07391-6
pubmed: 35578185
pmcid: 9109386